volume 31, issue 8, P2393-2399 1992
DOI: 10.1021/bi00123a026
View full text
|
|
Share
Jos Veldscholte, Cor A. Berrevoets, Albert O. Brinkmann, J. Anton Grootegoed, Eppo Mulder

Abstract: Previous studies from this laboratory have described that LNCaP prostate tumor cells contain an androgen receptor (AR) with a point mutation in the steroid-binding domain (codon 868, Thr to Ala). This defect leads to a change in specificity of the AR. Estrogens, progestagens, and some anti-androgens (e.g., cyproterone acetate, hydroxyflutamide, nilutamide) stimulate LNCaP cell growth rate through the AR. The present studies indicate that not all anti-androgens showed agonistic effects with the mutated receptor…

expand abstract